Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Letter to the Editor

Volume 12, Number 8, August 2020, pages 539-541

Are Patients With Autoimmune Disease at Greater Risk of Developing Severe COVID-19?

Table

Table 1. Comparison of Outcome and Laboratory Values on Admission Between COVID-19 Patients With Comorbid Autoimmune Disease and COVID-19 Patients Without Autoimmune Disease in a Single Center in Western Greece
 
Inpatients with comorbid autoimmune disease (n = 7)Inpatients without comorbid autoimmune disease (n = 14)Normal range of parameters comparedP value
COVID-19: coronavirus disease 2019; SD: standard deviation; WBC: white blood cell; TNF: tumor necrosis factor; IL: interleukin.
Sex (male/female), %0/10014.3/85.7-0.481
Age, years (mean ± SD)57 ± 2164.6 ± 6.8--
Immune-modulatory therapiesYes: interferon α, anti-TNF-α, anti-IL-6No--
Duration of hospitalization, days (mean ± SD)7.14 ± 2.68 ± 3.1-0.771
Serum ferritin (mean ± SD)442 ± 200319.7 ± 8812 - 300 mg/dL (male); 12 - 150 mg/dL (female)0.800
Plasma D-dimers (mean ± SD)762.5 ± 104.21,090 ± 1,131.4< 500 µg/dL0.667
Lactate dehydrogenase (mean ± SD)307.5 ± 92.3277.7 ± 55.07120 - 220 U/L0.945
Plasma fibrinogen (mean ± SD)424.5 ± 104624 ± 135.6200 - 400 mg/dL0.114
Lymphocyte count (mean ± SD)1,806.5 ± 897.61,242.1 ± 355.820-50% of WBC, k/µL0.445
Mortality (n)00-